Loading…
Employees: 65
Size SK Discovery (006120.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $804M, the 263rd largest of 495 South Korea companies the cockpit tracks. Shares closed at ₩62,200 on 6 Nov 2026.
Performance Over six months the shares gained 11.3%, against -8.0% for the median peer and -24.5% for the South Korea market (cap-weighted) — 4th highest of 20 in its peer set.
Growth Revenue grew 20.1% over the last twelve months (peer median +2.7%); the operating margin is 2.8% (peer median 10.1%).
Valuation It trades at 0.8× enterprise value to sales against a peer median of 2.9× (2nd cheapest of 19).
Capital Return on invested capital runs 3.6 points below its cost of capital (5.0% WACC).
Next results Next results expected around 12 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩11.6T | ₩10.2T | ₩9.04T | ₩8.94T | ₩8.72T |
| Revenue growth | — | +12% | +1% | +3% | — |
| Gross profit | ₩1.23T | ₩1.20T | ₩936B | ₩963B | ₩767B |
| EBITDA | ₩879B | ₩884B | ₩540B | ₩603B | ₩543B |
| Net income | ₩188B | ₩129B | ₩36.5B | ₩191B | ₩427B |
| Free cash flow | -₩186B | -₩143B | -₩774B | -₩393B | -₩532B |
| Capital expenditure | ₩876B | ₩843B | ₩833B | ₩971B | ₩625B |
| Total debt | ₩8.24T | ₩7.26T | ₩6.44T | ₩4.77T | ₩4.13T |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 006120.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -13.5% | -3.3% | 3rd lowest of 20 |
| 6-month return | +11.3% | -8.0% | 4th highest of 20 |
| Distance from 52-week high | -14.8% | -32.0% | 3rd highest of 20 |
| Revenue growth (TTM) | +20.1% | +2.7% | 3rd highest of 19 |
| Operating margin | 2.8% | 10.1% | 7th lowest of 19 |
| EV / Sales | 0.8× | 2.9× | 2nd cheapest of 19 |
| ROIC minus cost of capital | -3.6 pp | +2.1 pp | 4th lowest of 17 |
| EV / EBITDA | 11.2× | 11.6× | 4th cheapest of 8 |
| Net debt / EBITDA | 4.6× | -0.5× | most indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| SK Discovery 006120.KS | South Korea | $804M | +11% | +20% | 3% | 0.8× | n/a | n/a |
| Alumis ALMS | United States | $805M | -27% | -63% | -5,480% | 45.8× | n/a | n/a |
| Guizhou Xinbang Pharmaceutical 002390.SZ | China | $805M | -10% | -13% | 4% | 0.9× | -3.0% | -0.8% |
| Zhejiang Anglikang Pharmaceutical 002940.SZ | China | $801M | -19% | -6% | 10% | 4.2× | 18.2% | +2.1% |
| Knight Therapeutics GUD.TO | Canada | $800M | +37% | +42% | 5% | 1.9× | 9.5% | +17.7% |
| Sanofi India SANOFI.NS | India | $800M | -3% | -6% | 26% | 4.2× | 16.5% | -8.7% |
| Chongqing Pharscin Pharmaceutical 002907.SZ | China | $808M | -7% | +8% | 10% | 5.7× | 10.7% | -1.4% |
| Annexon ANNX | United States | $796M | -26% | n/a | n/a | n/a | n/a | n/a |
| Suven Life Sciences SUVEN.NS | India | $792M | +20% | +17% | -4,228% | 849.2× | n/a | n/a |
| Lexicon Pharmaceuticals LXRX | United States | $792M | -11% | -29% | -131% | 15.9× | n/a | n/a |
| Katakura Industries 3001.T | Japan | $791M | +46% | 0% | 16% | 2.5× | 0.2% | +0.5% |
| Hunan Jiudian Pharmaceutical 300705.SZ | China | $789M | -18% | -5% | 13% | 1.9× | -1.1% | +26.1% |
| Collegium Pharmaceutical COLL | United States | $788M | -36% | +14% | 20% | 2.3× | -7.0% | +20.3% |
| Zhuzhou Qianjin Pharmaceutical 600479.SS | China | $787M | -3% | +4% | 11% | 1.4× | -1.4% | 0.0% |
| Jinghua Pharmaceutical 002349.SZ | China | $825M | -8% | +2% | 20% | 3.2× | -1.8% | +2.6% |
| CARsgen Therapeutics 2171.HK | Hong Kong | $825M | -54% | +68% | -170% | 32.3× | n/a | n/a |
| Bambusa Therapeutics BBTX | United States | $783M | n/a | n/a | n/a | n/a | n/a | n/a |
| Zhejiang Int'l 000411.SZ | China | $828M | -8% | +3% | 3% | 0.3× | n/a | n/a |
| Jiangsu Jibeier Pharmaceutical 688566.SS | China | $777M | -8% | +9% | 24% | 4.3× | 11.5% | +11.3% |
| Youcare Pharmaceutical 688658.SS | China | $776M | -41% | -7% | -13% | 2.0× | n/a | n/a |
| DongKook Pharmaceutical 086450.KS | South Korea | $776M | -1% | +13% | 10% | 1.1× | -6.3% | +10.6% |